Markets

Retrophin (RTRX) Jumps: Stock Adds 13.5% in Session - Tale of the Tape

Retrophin, Inc. ( RTRX ) was a big mover last session with its shares rising nearly 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company as the stock is now trading way above the past one month's volatile price range of $10.99 to $14.35.

This biopharmaceutical company has seen one negative estimate revision in the last 30 days. The Zacks Consensus Estimate has also moved lower over the same time frame. This implies trouble down the road. So make sure to keep an eye on this stock going forward to see if Friday's rally can last.

Retrophin currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Investors interested in the biomedical industry may consider better-ranked stocks like Myriad Genetics Inc. ( MYGN ), Gilead Sciences Inc. ( GILD ) and Illumina Inc. ( ILMN ). All the three stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

RETROPHIN INC (RTRX): Get Free Report

MYRIAD GENETICS (MYGN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

ILLUMINA INC (ILMN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MYGN GILD RTRX ILMN

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More